OncoCyte (OCX) Q4 Earnings Match Estimates, Revenues Lag (Revised)

OncoCyte (OCX) came out with a quarterly loss of $0.10 per share, in line with the Zacks Consensus Estimate. This compares to loss of $0.09 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of 0%. A quarter ago, it was expected that this cancer diagnostic test developer would post a loss of $0.07 per share when it actually produced a loss of $0.11, delivering a surprise of -57.14%.

Over the last four quarters, the company has surpassed consensus EPS estimates just once.

OncoCyte, which belongs to the Zacks Medical Services industry, posted revenues of $3.59 million for the quarter ended December 2021, missing the Zacks Consensus Estimate by 17.49%. This compares to year-ago revenues of $0.5 million. The company has topped consensus revenue estimates two times over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

OncoCyte shares have lost about 40.1% since the beginning of the year versus the S&P 500's decline of -10.3%.

What's Next for OncoCyte?

While OncoCyte has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for OncoCyte: mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.12 on $3.3 million in revenues for the coming quarter and -$0.38 on $21.35 million in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical Services is currently in the bottom 34% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

Biodesix, Inc. (BDSX), another stock in the same industry, has yet to report results for the quarter ended December 2021. The results are expected to be released on March 14.

This company is expected to post quarterly loss of $0.50 per share in its upcoming report, which represents a year-over-year change of -100%. The consensus EPS estimate for the quarter has been revised 5.4% higher over the last 30 days to the current level.

Biodesix, Inc.'s revenues are expected to be $7.33 million, down 72.9% from the year-ago quarter.

(We are reissuing this article to correct a mistake. The original article, issued on March 10, 2022, should no longer be relied upon.)

Just Released: Zacks Top 10 Stocks for 2022

In addition to the investment ideas discussed above, would you like to know about our 10 top picks for the entirety of 2022?

From inception in 2012 through 2021, the Zacks Top 10 Stocks portfolios gained an impressive +1,001.2% versus the S&P 500’s +348.7%. Now our Director of Research has combed through 4,000 companies covered by the Zacks Rank and has handpicked the best 10 tickers to buy and hold. Don’t miss your chance to get in…because the sooner you do, the more upside you stand to grab.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.